| Literature DB >> 32397278 |
Pedro Moreno-Navarro1, Ramón Gomez-Illán1, Carmen Carpena-Juan1, Ángel P Sempere2,3, Francisco J Vera-Garcia1, David Barbado1.
Abstract
Disability progression is a prominent feature of multiple sclerosis (MS). However, little is known about the extent to which physical condition parameters and perceived fatigue evolve during the disease. We analyzed how strength, balance, core stability and perceived fatigue differ among different cohorts of people with MS (PwMS) with different disability degrees and how these contribute to patients' gait speed and functional mobility. Sixty-three PwMS divided into three groups according to the "Expanded Disability Status Scale" (MS1: EDSS ≤ 1.5; MS2: 2 ≤ EDSS ≤ 3.5; MS3: 4 ≤ EDSS ≤ 6) and 22 healthy controls (HC) participated in this study. MS1 showed lower balance and hip strength compared to HC. MS2 showed lower balance, core stability, gait speed, and functional mobility than MS1. MS3 showed lower gait speed, functional mobility, balance, and knee flexion strength than MS2. No between-group differences were observed in perceived fatigue. Relative weight analysis showed that strength, balance and core stability explained 60%-70% of the variance in gait speed and functional mobility. The decline of each parameter did not evolve at the same rate across the different stages of the disease, being knee flexion strength and balance the most influential factors in the disability progression. Overall, these results provide useful information to guide exercise prescription at different stages of MS.Entities:
Keywords: balance; gait; neurodegeneration; perceived fatigue; relative weight analysis; strength
Year: 2020 PMID: 32397278 PMCID: PMC7290682 DOI: 10.3390/jcm9051385
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Demographic, clinical characteristics and medications of the healthy controls and multiple sclerosis individuals stratified according to their Expanded Disability Status Scale (EDSS).
| HC | MS1 | MS2 | MS3 | F |
| |
|---|---|---|---|---|---|---|
|
| 40.23 ± 8.15 | 36.70 ± 7.33 | 44.96 ± 7.77 * | 44.65 ± 8.03 * | 5.24 | 0.002 |
|
| 165.34 ± 7.79 | 167.73 ± 9.68 | 163.57 ± 7.68 | 166.25 ± 10.64 | 0.32 | 0.812 |
|
| 66.99 ± 14.05 | 67.41 ± 10.07 | 64.21 ± 11.49 | 65.84 ± 15.17 | 0.81 | 0.494 |
|
| - | 1.10 ± 0.60 | 2.83 ± 0.51 | 5.08 ± 1.00 | 150.28 | <0.001 |
|
| 6.15 ± 4.31 | 9.96 ± 5.30 | 11.60 ± 6.91 * | 5.02 | 0.010 | |
|
| 18/4 | 16/4 | 20/3 | 13/7 | ||
|
| ||||||
| Relapsing remitting | - | 20 | 21 | 13 | ||
| Secondary progressive | - | - | 1 | 6 | ||
| Primary progressive | - | - | 1 | 1 | ||
|
| ||||||
| Alemtuzumab | - | 1 | 2 | 1 | ||
| Azathioprine | - | 0 | 1 | 0 | ||
| Dimethyl-fumarate | - | 0 | 3 | 1 | ||
| Fingolimod | - | 1 | 6 | 3 | ||
| Interferon-beta | - | 4 | 4 | 2 | ||
| Natalizumab | - | 7 | 1 | 2 | ||
| Ocrelizumab | - | 0 | 1 | 1 | ||
| Rituximab | - | 0 | 1 | 3 | ||
| Teriflunomide | - | 2 | 2 | 0 | ||
| Glatiramer acetate | - | 2 | 2 | 2 | ||
| None | - | 3 | 0 | 5 | ||
|
| - | 0 | 0 | 6 |
Note. Values are mean scores ± SD or as otherwise indicated. SD: standard deviation; HC: healthy controls; MS1: multiple sclerosis people with minimal or non-impairment (EDSS ≤ 1.5); MS2: multiple sclerosis people with mild impairment (2 ≤ EDSS ≤ 3.5); MS3: multiple sclerosis people with moderate impairment (4 ≤ EDSS ≤ 6). *: significantly different from MS1.
Comparison of strength, balance, core stability and perceived fatigue parameters between healthy controls (n = 22) and multiple sclerosis individuals with minimal (n = 20), mild (n = 23) and moderate impairment (n = 20).
| Effect Size (Hedge’s | Percentage Differences | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HC | MS1 | MS2 | MS3 | F |
| HC vs. MS1 | MS1 vs. MS2 | MS2 vs.MS3 | HC vs. MS1 | HC vs. MS2 † | HC vs. MS3 †† | |
|
| ||||||||||||
|
| 863.4 ± 145.4 | 746.6 ± 220.1 | 558.7 ± 125.6 | 322.3 ± 135.2 | 45.62 | <0.001 | 0.62 | 1.05 * | 1.78 * | 13.5 ± 25.5 | 35.3 ± 14.5 | 62.7 ± 15.7 |
|
| 2.50 ± 0.32 | 2.70 ± 0.38 | 3.24 ± 0.50 | 6.41 ± 1.67 | 86.74 | <0.001 | 0.55 | 1.19 * | 2.61 * | 7.8 ± 15.1 | 29.6 ± 20.0 | 156.3 ± 66.7 |
|
| 4.70 ± 0.55 | 5.10 ± 0.58 | 5.86 ± 0.97 | 10.32 ± 2.54 | 71.09 | <0.001 | 0.69 | 0.91 * | 2.34 * | 8.4 ± 12.4 | 24.5 ± 20.6 | 119.3 ± 53.9 |
|
| ||||||||||||
|
| 7.94 ± 1.85 | 10.92 ± 3.03 | 14.99 ± 4.96 | 25.91 ± 8.29 | 46.43 | <0.001 | 1.18 * | 0.96 * | 1.64 * | 37.5 ± 38.1 | 88.8 ± 62.5 | 226.4 ± 104.4 |
|
| 7.22 ± 1.74 | 9.09 ± 2.17 | 12.77 ± 4.13 | 20.45 ± 7.30 | 36.17 | <0.001 | 0.94 * | 1.07 * | 1.31 * | 25.9 ± 30.1 | 76.9 ± 57.2 | 183.2 ± 101.1 |
|
| 8.35 ± 3.22 | 10.79 ± 3.56 | 15.45 ± 5.40 | 23.91 ± 10.75 | 23.78 | <0.001 | 0.71 | 0.96 * | 1.00 * | 29.2 ± 42.6 | 85.1 ± 64.7 | 186.5 ± 128.7 |
|
| - | 23.08 ± 20.01 | 32.09 ± 19.26 | 47.70 ± 17.20 | 8.26 | 0.001 | - | 0.47 | 0.75 * | - | - | - |
|
| ||||||||||||
|
| 1.90 ± 0.35 | 1.74 ± 0.39 | 1.43 ± 0.38 | 1.22 ± 0.46 | 12.41 | <0.001 | 0.43 | 0.77 | 0.50 | 8.7 ± 20.7 | 24.7 ± 20.1 | 35.9 ± 24.1 |
|
| 2.03 ± 0.37 | 1.92 ± 0.38 | 1.61 ± 0.37 | 1.55 ± 0.35 | 8.54 | <0.001 | 0.30 | 0.79 * | 0.18 | 5.7 ± 18.8 | 20.6 ± 18.2 | 23.8 ± 17.3 |
|
| 0.91 ± 0.21 | 0.80 ± 0.21 | 0.65 ± 0.21 | 0.37 ± 0.24 | 24.37 | <0.001 | 0.54 | 0.69 | 1.24 * | 12.4 ± 22.7 | 28.3 ± 22.7 | 58.9 ± 25.8 |
|
| 1.01 ± 0.21 | 0.94 ± 0.18 | 0.80 ± 0.16 | 0.61 ± 0.22 | 16.81 | <0.001 | 0.33 | 0.81 | 0.97 * | 6.6 ± 18.1 | 20.7 ± 16.1 | 39.3 ± 21.7 |
|
| ||||||||||||
|
| 2.32 ± 0.93 | 1.67 ± 0.58 | 1.42 ± 0.38 | 1.36 ± 0.38 | 12.25 | <0.001 | 0.82 * | 0.49 | 0.17 | 28.2 ± 24.9 | 38.7 ± 16.4 | 41.4 ± 16.2 |
|
| 2.62 ± 1.07 | 1.97 ± 0.57 | 1.61 ± 0.40 | 1.59 ± 0.42 | 11.00 | <0.001 | 0.73 | 0.74 | 0.03 | 24.7 ± 21.7 | 38.6 ± 15.1 | 39.2 ± 16.2 |
|
| 2.70 ± 0.95 | 1.89 ± 0.48 | 1.64 ± 0.39 | 1.39 ± 0.51 | 17.93 | <0.001 | 1.04 * | 0.58 | 0.53 | 29.9 ± 17.7 | 39.4 ± 14.6 | 48.6 ± 19.0 |
|
| 3.10 ± 0.94 | 2.18 ± 0.50 | 1.81 ± 0.43 | 1.79 ± 0.52 | 20.43 | <0.001 | 1.18 * | 0.78 | 0.04 | 29.7 ± 16.0 | 41.6 ± 14.0 | 42.2 ± 16.7 |
|
| ||||||||||||
|
| - | 40.55 ± 15.29 | 44.83 ± 12.01 | 40.95 ± 14.97 | 0.620 | 0.54 | - | 0.31 | −0.28 | - | - | - |
Note. Values are mean scores ± SD. For Hedges’ g and Percentage differences, positive scores indicate a deterioration of the group with higher EDSS scores compared to the group with lower EDSS scores or with the control group. † MS2 showed significant pairwise differences in all parameters compared to HC; †† MS3 showed significant pairwise differences in all parameters compared to HC and MS1; * Significant differences between groups at p < 0.05 adjusted with the Tukey or Games–Howell corrections when the assumption of homogeneity of variances is or is not accomplished, respectively. SD: standard deviation; HC: healthy controls; MS1: multiple sclerosis people with minimal impairment (EDSS ≤ 1.5); MS2: multiple sclerosis people with mild impairment (2 ≤ EDSS ≤ 3.5); MS3: multiple sclerosis people with moderate impairment (4 ≤ EDSS ≤ 6); EDSS: Expanded Disability Status Scale; 6MWT: 6-min Walk test (m); T25FW: Timed 25-Foot Walk test (s); TUG: Timed Up & Go test (s); TSWL: Tandem Stance Balance test with the weakest leg behind (mm); TSSL: tandem stance balance test with the strongest leg behind (mm); US: Unstable Sitting Balance test (mm); DHI: Dizziness Handicap Inventory (unitless); EXTWL: isokinetic knee extension peak torque for the weakest leg (N×m/kg); EXTSL: isokinetic knee extension peak torque for the strongest leg (N×m/kg); FLXWL: isokinetic knee flexion peak torque for the weakest leg (Nm/kg); FLXSL: isokinetic knee flexion peak torque for the strongest leg (Nm/kg); ADDWL: isometric hip adduction peak force for the weakest leg (N/kg); ADDSL: isometric hip adduction peak force for the strongest leg (N/kg); ABDWL: isometric hip abduction peak force for the weakest leg (N/kg); ABDSL: isometric hip abduction peak force for the strongest leg (N/kg); MFIS: Modified Fatigue Impact Scale (unitless).
Relative Weight Analysis with the 6MWT, T25FW and TUG as the dependent variables and their significant (p < 0.05) predictive factor (PF) in people with multiple sclerosis (n = 61).
| Explained Variance (%, Adjusted R2) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | 1st PF | 2nd PF | 3rd PF | 4th PF | 5th PF | 6th PF | 7th PF | 8th PF | 9th PF | ||
|
| 71.0 |
| FLXWL | FLXSL | TSWL | TSSL | EXTWL | ABDSL | DHI | EXTSL | ABDWL |
|
| 16.4 | 14.8 | 7.7 | 7.0 | 6.4 A | 4.9 | 4.9 | 4.5 | 4.3 | ||
|
| (10.6–22.7) | (9.1–21.7) | (3.6–12.3) | (2.9–13.2) | (2.7–10.9) | (1.4–9.3) | (1.4–9.9) | (1.6–8.4) | (1.3–7.6) | ||
|
| 60.6 |
| FLXWL | TSWL | FLXSL | US | EXTWL | ||||
|
| 18.8 | 18.2 | 11.6 | 7.4 | 4.6 A,B | ||||||
|
| (7.8–31.3) | (7.9–34.5) | (5.3–20.2) | (1.9–17.4) | (1.5–9.7) | ||||||
|
| 61.7 |
| FLXWL | TSWL | US | FLXSL | EXTWL | DHI | |||
|
| 16.8 | 13.3 | 11.3 | 9.4 | 5.7 A | 5.2 A | |||||
|
| (6.5–28.9) | (4.9–27.7) | (4.1–22.8) | (3.5–14.9) | (1.6–11.4) | (1.2–11.6) | |||||
A: significant differences compared to the 1th PF; B: significant differences compared to the 2th PF; CI: Confidence interval; 6MWT: 6-min Walk test (m); T25FW: Timed 25-Foot Walk test (s); TUG: Timed Up & Go test (s); TSSL: Tandem Stance Balance test with the strongest leg behind (mm);TSWL: Tandem Stance Balance test with the weakest leg behind (mm); US: Unstable Sitting Balance test (mm); EXTWL: isokinetic knee extension peak torque for the weakest leg (Nm/kg); EXTSL: isokinetic knee extension peak torque for the strongest leg (Nm/kg); FLXWL: isokinetic knee flexion peak torque for the weakest leg (Nm/kg); FLXSL: isokinetic knee flexion peak torque for the strongest leg (Nm/kg); ABDWL: isometric hip abduction peak force for the weakest leg (N/kg); ABDSL: isometric hip abduction peak force for the strongest leg (N/kg); DHI: Dizziness Handicap Inventory (unitless).
Rehabilitation priorities for people with multiple sclerosis according to the EDSS stage.
| Main Target | Complementary Activities | |
|---|---|---|
|
| Balance exercises | Lower limb resistance training |
|
| Comprehensive program. | Knee flexors resistance exercises |
|
| Knee flexors resistance exercises | Core stability exercises |
MS1: multiple sclerosis people with minimal impairment (EDSS ≤ 1.5); MS2: multiple sclerosis people with mild impairment (2 ≤ EDSS ≤ 3.5); MS3: multiple sclerosis people with moderate impairment (4 ≤ EDSS ≤ 6). Recommendations provided in the “Main Target” section were based on the main deficits observed in each multiple sclerosis group analyzed in this study. Recommendations provided in the “Complementary Activities” section were carried out to avoid the deficits that will probably occur in the next stage of the multiple sclerosis disease.